Skip to main content

Talking Therapeutics

Jennings Headshot
Talking Therapeutics
11/14/2024
In this installment of Talking Therapeutics, we discuss a new study that explores the effect of various interventions aimed at combating sedentary behavior on blood pressure and pulse wave velocity (PWV), a key marker of arterial stiffness.
In this installment of Talking Therapeutics, we discuss a new study that explores the effect of various interventions aimed at combating sedentary behavior on blood pressure and pulse wave velocity (PWV), a key marker of arterial stiffness.
In this installment of Talking...
11/14/2024
Pharmacy Learning Network
Jennings Headshot
Talking Therapeutics
11/08/2024
In this installment of Talking Therapeutics, we discuss new data comparing empagliflozin and dapagliflozin in patients with diabetes that show no difference in cardiovascular outcomes, underscoring the need for further studies.
In this installment of Talking Therapeutics, we discuss new data comparing empagliflozin and dapagliflozin in patients with diabetes that show no difference in cardiovascular outcomes, underscoring the need for further studies.
In this installment of Talking...
11/08/2024
Pharmacy Learning Network
Jennings Headshot
Talking Therapeutics
10/11/2024
In this installment of Talking Therapeutics, we explore a first-of-its-kind trial evaluating the potential of SGLT2 inhibitors to prevent chemotherapy-related cardiotoxicity.
In this installment of Talking Therapeutics, we explore a first-of-its-kind trial evaluating the potential of SGLT2 inhibitors to prevent chemotherapy-related cardiotoxicity.
In this installment of Talking...
10/11/2024
Pharmacy Learning Network
Jennings Headshot
Talking Therapeutics
10/07/2024
In this installment of Talking Therapeutics, we explore whether the novel medication finerenone, which has a demonstrated benefit in patients with kidney disease, can also improve outcomes in patients with HFpEF.
In this installment of Talking Therapeutics, we explore whether the novel medication finerenone, which has a demonstrated benefit in patients with kidney disease, can also improve outcomes in patients with HFpEF.
In this installment of Talking...
10/07/2024
Pharmacy Learning Network
Douglass Jennings
Talking Therapeutics
07/19/2024
In this installment of Talking Therapeutics, Dr Jennings explores a new study that evaluates dapagliflozin against empagliflozin in patients with heart failure.
In this installment of Talking Therapeutics, Dr Jennings explores a new study that evaluates dapagliflozin against empagliflozin in patients with heart failure.
In this installment of Talking...
07/19/2024
Pharmacy Learning Network
Jennings Headshot
Talking Therapeutics
06/24/2024
In this installment of Talking Therapeutics, Dr Jennings reviews a study demonstrating that racial bias in medicine may prevent positive treatment outcomes for Black patients with hypertension and heart failure with a reduced ejection...
In this installment of Talking Therapeutics, Dr Jennings reviews a study demonstrating that racial bias in medicine may prevent positive treatment outcomes for Black patients with hypertension and heart failure with a reduced ejection...
In this installment of Talking...
06/24/2024
Pharmacy Learning Network
Douglas Jennings
Talking Therapeutics
06/06/2024
In this week's installment of Talking Therapeutics, Dr Jennings explores a new trial that evaluates the impact of GLP-1 agonists on kidney and cardiovascular endpoints in patients with diabetes and chronic kidney disease.
In this week's installment of Talking Therapeutics, Dr Jennings explores a new trial that evaluates the impact of GLP-1 agonists on kidney and cardiovascular endpoints in patients with diabetes and chronic kidney disease.
In this week's installment of...
06/06/2024
Pharmacy Learning Network
Douglas Jennings
Talking Therapeutics
05/24/2024
In this installment of Talking Therapeutics, Dr Jennings explores a new paper outlining the potential benefit of statins on key outcomes in patients with heart failure with preserved ejection fraction (HFpEF).
In this installment of Talking Therapeutics, Dr Jennings explores a new paper outlining the potential benefit of statins on key outcomes in patients with heart failure with preserved ejection fraction (HFpEF).
In this installment of Talking...
05/24/2024
Pharmacy Learning Network
Jennings Headshot
Talking Therapeutics
05/09/2024
In this installment of Talking Therapeutics, Dr Jennings explores another potentially dangerous direct-acting oral anticoagulant (DOAC) combination based on a recent study.
In this installment of Talking Therapeutics, Dr Jennings explores another potentially dangerous direct-acting oral anticoagulant (DOAC) combination based on a recent study.
In this installment of Talking...
05/09/2024
Pharmacy Learning Network
Talking Therapeutics
04/25/2024
In this installment of Talking Therapeutics, Dr Jennings analyzes recent study findings determining efficacy of dapagliflozin in patients with acute heart failure.
In this installment of Talking Therapeutics, Dr Jennings analyzes recent study findings determining efficacy of dapagliflozin in patients with acute heart failure.
In this installment of Talking...
04/25/2024
Pharmacy Learning Network